{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T20:46:42Z","timestamp":1782420402639,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peyronie\u2019s disease (PD) is an acquired connective tissue disorder characterized by fibrous plaque formation within the penile tunica albuginea that may be influenced by androgen status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate whether baseline testosterone levels and testosterone therapy (TTh) during collagenase clostridium histolyticum (CCH) treatment affect curvature severity and treatment outcomes in men with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-center retrospective study included men with PD treated with CCH who had no curvature progression in the preceding three months and documented baseline testosterone levels. Demographics, baseline and post-treatment curvature, pain, plaque calcification, adverse events, TTh use, and surgical conversion were analyzed. Testosterone deficiency was defined as testosterone &amp;lt;300\u00a0ng\/dL and concurrent signs or symptoms of low testosterone. Multivariable analyzes assessed predictors of curvature improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Primary outcomes included change in penile curvature following CCH therapy and secondary outcomes included adverse events and surgical conversion rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 790 men, 778 met inclusion criteria (mean age 56.6\u2009\u00b1\u20099.1\u00a0years), with a median of eight CCH injections. Testosterone deficiency was present in 21% (n\u2009=\u2009166), of whom 54% (n\u2009=\u200990) received TTh. Baseline curvature was similar among eugonadal men, testosterone deficient men on TTh, and testosterone deficient men not receiving therapy (45\u00b0 vs. 44\u00b0 vs. 48\u00b0, P\u2009=\u2009.392), as were pain symptoms and disease duration, though plaque calcification was more common in testosterone deficient men (P\u2009=\u2009.039). Mean curvature improvement was greatest in eugonadal men (24\u00b0), followed by testosterone deficient men on TTh (19\u00b0) and testosterone deficient men without therapy (17\u00b0). On multivariable analysis adjusting for age, baseline erectile dysfunction, baseline curvature severity, plaque calcification and post procedure modeling, both testosterone deficient groups remained independently associated with less curvature improvement compared with eugonadal men, with no significant difference between testosterone deficient men receiving versus not receiving TTh. Testosterone deficient men experienced higher rates of pain requiring medication (P\u2009&amp;lt;\u2009.05). Other adverse events and surgical conversion rates were similar across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>Baseline androgen status may influence response to CCH therapy and should be considered during counseling and treatment planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>Strengths include a large multi-center cohort and multivariable analysis, while limitations include retrospective design, variability in TTh regimens, and potential unmeasured confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Testosterone deficiency is associated with reduced curvature improvement following CCH therapy regardless of testosterone treatment, with eugonadal men demonstrating the greatest therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag185","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T11:35:26Z","timestamp":1780227326000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of testosterone therapy and hypogonadism on treatment outcomes in Peyronie\u2019s disease: a multicenter retrospective analysis of collagenase\n                    <i>clostridium histolyticum<\/i>\n                    therapy"],"prefix":"10.1093","volume":"23","author":[{"given":"Beatriz S","family":"Hernandez","sequence":"first","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaav","family":"Walia","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6919-9170","authenticated-orcid":false,"given":"Peyton","family":"Coady","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Angulo-Llanos","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Miami Miller School of Medicine , Miami , 33146,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L","family":"Bernie","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University , Carmel, 46032, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas G C R","family":"de Amorim","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University , Carmel, 46032, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah R","family":"Dallmer","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University , Carmel, 46032, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-1364","authenticated-orcid":false,"given":"Muhammed A","family":"Moukhtar Hammad","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, 92697, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Chin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , San Diego, 92093, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0233-0607","authenticated-orcid":false,"given":"David E","family":"Hinojosa-Gonzalez","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Kava","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Miami Miller School of Medicine , Miami , 33146,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Masterson","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Miami Miller School of Medicine , Miami , 33146,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake A","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, 92697, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0864-2898","authenticated-orcid":false,"given":"Thairo A","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University , Carmel, 46032, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3053-5828","authenticated-orcid":false,"given":"Gal","family":"Saffati","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , San Diego, 92093, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A","family":"Yaf","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, 92697, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Khera","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX , 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"2026062515474013800_ref1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"5","key":"2026062515474013800_ref2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.ijir.3900863","article-title":"Epidemiology of Peyronie's disease","volume":"14","author":"Sommer","year":"2002","journal-title":"Int J Impot Res"},{"issue":"2","key":"2026062515474013800_ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: a population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"2026062515474013800_ref4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"6","key":"2026062515474013800_ref5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"issue":"Pt 4","key":"2026062515474013800_ref6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1242\/jcs.02786","article-title":"Androgens modulate the inflammatory response during acute wound healing","volume":"119","author":"Gilliver","year":"2006","journal-title":"J Cell Sci"},{"issue":"5","key":"2026062515474013800_ref7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bbi.2008.12.001","article-title":"Sex hormones and mucosal wound healing","volume":"23","author":"Engeland","year":"2009","journal-title":"Brain Behav Immun"},{"issue":"6","key":"2026062515474013800_ref8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/j.1743-6109.2009.01250.x","article-title":"Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship","volume":"6","author":"Moreno","year":"2009","journal-title":"J Sex Med"},{"issue":"11","key":"2026062515474013800_ref9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1442-2042.2011.02842.x","article-title":"Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease?","volume":"18","author":"Nam","year":"2011","journal-title":"Int J Urol"},{"issue":"3","key":"2026062515474013800_ref10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2164\/jandrol.111.012948","article-title":"Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations","volume":"33","author":"Cavallini","year":"2012","journal-title":"J Androl"},{"key":"2026062515474013800_ref11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"issue":"6","key":"2026062515474013800_ref12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/10742484211032402","article-title":"Testosterone deficiency, long-term testosterone therapy, and inflammation","volume":"26","author":"Zhang","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"2026062515474013800_ref13","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001263","article-title":"The role of androgens on experimental pain sensitivity: a systemic review and meta-analysis","volume":"10","author":"Wu-Chen","year":"2025","journal-title":"Pain Rep"},{"issue":"1","key":"2026062515474013800_ref14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00345-002-0251-x","article-title":"The ageing male and erectile dysfunction","volume":"20","author":"Montorsi","year":"2002","journal-title":"World J Urol"},{"issue":"Suppl 1","key":"2026062515474013800_ref15","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1186\/1471-2482-12-S1-S24","article-title":"Testosterone deficiency causes penile fibrosis and organic erectile dysfunction in aging men. Evaluating association among age, TDS and ED","volume":"12 Suppl 1","author":"Iacono","year":"2012","journal-title":"BMC Surg"},{"issue":"12","key":"2026062515474013800_ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120549","article-title":"Do androgens modulate the pathophysiological pathways of inflammation? Appraising the contemporary evidence","volume":"7","author":"Traish","year":"2018","journal-title":"J Clin Med"},{"issue":"8","key":"2026062515474013800_ref17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jsxm.2019.05.021","article-title":"Testosterone levels are not associated with magnitude of deformity in men with Peyronie's disease","volume":"16","author":"Mulhall","year":"2019","journal-title":"J Sex Med"},{"issue":"8","key":"2026062515474013800_ref18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41443-020-0340-7","article-title":"Serum testosterone levels are not associated with the severity of penile curvature in men with Peyronie's disease-findings from a cross-sectional study","volume":"33","author":"Candela","year":"2020","journal-title":"Int J Impot Res"},{"issue":"1","key":"2026062515474013800_ref19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/iju.15055","article-title":"Significant inverse association of testosterone level with penile deformity severity in Japanese males with Peyronie's disease","volume":"30","author":"Mitsui","year":"2023","journal-title":"Int J Urol"},{"issue":"1","key":"2026062515474013800_ref20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/andro.2020.0006","article-title":"Augmenting intralesional collagenase treatment with testosterone therapy provides greater self-assessed improvement in penile curvature due to Peyronie's disease","volume":"1","author":"Shlykova","year":"2020","journal-title":"Androgens: Clinical Research and Therapeutics"},{"issue":"4","key":"2026062515474013800_ref21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/andr.13532","article-title":"Peyronie's disease response to intralesional collagenase clostridium histolyticum therapy is independent of baseline testosterone","volume":"12","author":"Schneider","year":"2024","journal-title":"Andrology"},{"key":"2026062515474013800_ref22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.urology.2023.09.037","article-title":"Serum testosterone concentration influences the response to extracorporeal shock wave treatment in men with Peyronie's disease","volume":"183","author":"Dell'Atti","year":"2024","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag185\/68615831\/qdag185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag185\/68615831\/qdag185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:47:47Z","timestamp":1782416867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag185\/8716607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag185","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]},"article-number":"qdag185"}}